Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)

This study has been completed.
Sponsor:
Information provided by:
University Hospital Inselspital, Berne
ClinicalTrials.gov Identifier:
NCT00614562
First received: January 31, 2008
Last updated: February 2, 2011
Last verified: February 2011

January 31, 2008
February 2, 2011
January 2008
June 2009   (final data collection date for primary outcome measure)
Changes in mean inspiratory electrical activity of the diaphragm (Edi) [ Time Frame: beginning to end of study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00614562 on ClinicalTrials.gov Archive Site
Changes in ventilatory and respiratory parameters Changes in sedative and vasoactive drugs used [ Time Frame: beginning to end of study ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)
Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M)

Neurally adjusted ventilatory assist (NAVA) is a new concept of mechanical ventilation. NAVA delivers assist to spontaneous breathing based on the detection of the electrical activity of the diaphragm. We study the effect of NAVA in patients with critical illness associated polyneuropathy / polymyopathy (CIP/M)

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Polyneuropathy
  • Polymyopathy
Device: Neurally adjusted ventilatory assist (NAVA)
NAVA for 72 hours
Experimental: NAVA
Intervention: Device: Neurally adjusted ventilatory assist (NAVA)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
December 2010
June 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Subject itself or its next of kin has given written informed consent
  2. Independent physician has given written informed consent
  3. Male or female patients aged 18 - 80 years (extremes included).
  4. Mechanical ventilation for ≥ 48 hours prior to enrolment
  5. Presence of Critical Illness Polyneuropathy / Polymyopathy (CIP/M) according to the MRC Scale for Muscle Examination in 12 Muscle groups (Table 1) with or without loss of sensibility and muscle reflexes.
  6. Presence of at least one of the following risk factors (A - D) known to be associated with CIP/M. Note, the risk factor does not need to be present at enrolment but needs to have been present prior to enrolment during the actual stay in the ICU:

    • A: severe sepsis defined as the presence of an infection is highly suspected or proven and three or more of the following systemic inflammatory response syndrome (SIRS) criteria are met (Bernard et al 2001 s. Figure 15):

      • core temperature greater than 38 degrees celsius (100.4 degrees F) or less than 36 degrees celsius (96.8 degrees F);
      • heart rate greater than 90 beats per minute;
      • respiratory rate greater than 20 breaths per minute, or arterial carbon dioxide tension (Paco2) greater than 32 mm Hg, or mechanical ventilation for an acute process;
      • a white cell count of more than 12 000/mm3 or less than 4000/mm3 , or a differential count showing more than 10% immature neutrophils.
    • B: MODS (s. Figure 15)
    • C: treatment with corticosteroids for at least 24 hours (either as repeated bolus or as continuous infusion).
    • D: treatment with neuro-muscular blocking agents for at least 24 hours (either as repeated bolus or as continuous infusion).

Exclusion Criteria:

  1. Patient is less than 18 years or more than 80 years of age
  2. The attending physician refuses to allow enrollment
  3. The patient refuses informed consent
  4. Next of kin is unavailable or refuses informed consent
  5. The independent physician refuses informed consent
  6. Pregnant or breast-feeding female. A pregnancy test will be performed in all female patients less than 60 years of age
  7. Any contraindication to insertion/exchange a nasogastric tube, including (but not limited to): severe oropharyngeal malformation or bleeding; esophageal varices, tumor, infection, stenosis, or rupture, bleeding disorder with evidence of active bleeding.
  8. Presence or suspicion of diaphragm injury
  9. Presence or suspicion of a central nervous system (CNS) proximal of the spinal cord level C2) including (but not limited to): infarction, bleeding, tumor, or infection in the CNS
  10. Presence or suspicion of any preexisting peripheral neuromuscular disorder.
  11. History of heart and/or lung transplantation
  12. Any mechanical cardiac assist device (excluding intraaortic balloon pump)
  13. Any contraindication to reduce sedation or to stop neuromuscular blockage in order to allow spontaneous breathing
  14. The patient needs to be ventilated with a mode of mechanical ventilation that targets a redefined tidal volume or airway pressure as per attending physician
  15. Severe hemodynamic instability as per attending physician
  16. A fraction of inspired oxygen (FiO2) of > 0.8 at enrollment.
  17. The patient currently participates in another interventional clinical trial
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00614562
KEK BE 250/07
No
Lukas Brander, MD, University Hospital - Inselspital
University Hospital Inselspital, Berne
Not Provided
Principal Investigator: Lukas Brander, MD Department of Intensive Care Medicine, University Hospital, Bern, Switzerland
University Hospital Inselspital, Berne
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP